Maya Khalil, MD

No bio available.

Financial relationships

  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Spectrum Pharmaceuticals, Inc
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Janssen Pharmaceutica Products, LP
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Caris Life Sciences
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Genentech, Inc
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    BeiGene
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Eli Lilly and Company
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Boehringer Ingelheim GmbH
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Other - ARCUS BioSciences
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    AstraZeneca Pharmaceuticals LP
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Other - TopAlliance Biosciences
    Topic:
    Principal or sub investigator on clinical trial
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
    Relationship end date:
    12/31/2027

Pages

Return to Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology